Mounjaro for Heart Failure: Off-Label Dosing Protocol, Evidence, and Clinical Guidance

The direct answer: there is no Mounjaro heart-failure dose

The current FDA Mounjaro prescribing information lists one indication: improving glycemic control, with diet and exercise, in adults and children age 10 or older with type 2 diabetes. Heart failure is not an indication in that label. Its dose-escalation instructions therefore describe treatment for type 2 diabetes; they are not an FDA-endorsed HFpEF protocol.

That distinction matters because a published trial can answer whether an intervention helped a defined research population without establishing how an individual with heart failure should start, increase, hold, or stop the drug. A trial schedule also does not create universal rules for changing diuretics, ordering biomarkers, or responding to weight loss.

The trial was SUMMIT, not “SURMOUNT-HFpEF”

The principal heart-failure trial was named SUMMIT. “SURMOUNT-HFpEF” is not the name of the final randomized HFpEF outcomes trial. SUMMIT enrolled 731 adults with symptomatic heart failure, a left-ventricular ejection fraction of at least 50%, and a body-mass index of at least 30. Participants were assigned to tirzepatide or placebo in addition to their background care, as described in Tirzepatide for Heart Failure with Preserved Ejection Fraction and Obesity.

Tirzepatide was titrated within the study to a maximum tolerated weekly dose, up to 15 mg. That fact describes the research methods. It does not mean every eligible patient reached 15 mg, that 15 mg is an HFpEF target, or that the study tested a single fixed “heart-failure dose.”

What the final SUMMIT publication found

During a median follow-up of 104 weeks, cardiovascular death or a worsening heart-failure event occurred in 36 of 364 participants assigned to tirzepatide (9.9%) and 56 of 367 assigned to placebo (15.3%). The reported hazard ratio was 0.62 (95% CI, 0.41 to 0.95), as reported in Tirzepatide for Heart Failure with Preserved Ejection Fraction and Obesity.

The components should not be blurred together. Worsening heart-failure events occurred in 29 participants taking tirzepatide and 52 taking placebo. Cardiovascular deaths occurred in 8 and 5 participants, respectively; that death comparison was imprecise and did not show a mortality reduction. The composite result should therefore not be rewritten as proof that tirzepatide lowers cardiovascular death by itself.

At 52 weeks, the Kansas City Cardiomyopathy Questionnaire Clinical Summary Score (KCCQ-CSS) improved by 19.5 points with tirzepatide and 12.7 points with placebo, a 6.9-point between-group difference. This supports better symptoms and physical limitations in the studied population. Gastrointestinal events were the main reason trial treatment was stopped: adverse events leading to discontinuation occurred in 6.3% of the tirzepatide group and 1.4% of the placebo group.

The primary results are reported in Tirzepatide for Heart Failure with Preserved Ejection Fraction and Obesity.

Who the evidence does and does not describe

The evidence is specific to an obesity-related HFpEF phenotype. SUMMIT required obesity, symptomatic heart failure, and preserved ejection fraction. It did not establish benefit for:

• heart failure with reduced ejection fraction (HFrEF);
• people with a body-mass index below 30;
• use of Mounjaro as a replacement for established heart-failure therapy;
• a person treating new breathlessness, swelling, or rapid weight change without clinical assessment; or
• a particular dose as the independently effective heart-failure dose.

The study also does not support choosing tirzepatide solely from a single lab value or body-composition measurement. A secondary SUMMIT analysis measured blood volume, inflammatory markers, kidney measures, natriuretic peptide, and troponin across randomized groups. Those findings help researchers explore mechanisms; they do not validate a home NT-proBNP schedule or a biomarker threshold for changing tirzepatide. See Effects of tirzepatide on circulatory overload and end-organ damage in heart failure with preserved ejection fraction and obesity: a secondary analysis of the SUMMIT trial.

Why a universal escalation or diuretic table is unsafe

Heart-failure weight changes can reflect several different processes: loss of body fat, reduced food or fluid intake, diuresis, worsening congestion, or loss of muscle and other lean tissue. A percentage change on the scale cannot identify which process is occurring. For the same reason, a fixed instruction to reduce a loop diuretic after a set amount of weight loss is not evidence-based.

The FDA Mounjaro prescribing information warns about acute kidney injury due to volume depletion, particularly in the setting of nausea, vomiting, or diarrhea. It also covers pancreatitis, gallbladder disease, severe gastrointestinal reactions, hypersensitivity, and a boxed warning concerning thyroid C-cell tumors observed in rats. Mounjaro is contraindicated in people with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2. When it is used with insulin or an insulin secretagogue, hypoglycemia risk can increase.

Those issues intersect with heart-failure care, but they do not yield a one-size-fits-all monitoring calendar. Kidney function, blood pressure, congestion, oral intake, diabetes medicines, and the reason for the prescription all affect clinical decisions. Changing a diuretic or tirzepatide from an online table could worsen either dehydration or fluid overload.

How to interpret the label schedule versus the trial schedule

The FDA label starts Mounjaro at 2.5 mg once weekly and increases it after four weeks for its approved type 2 diabetes indication, with later increases based on the need for additional glycemic control and tolerability. The label's adult maximum is 15 mg weekly. SUMMIT also used titration up to 15 mg, but similarity between schedules does not create a new indication.

For someone with both type 2 diabetes and HFpEF, a clinician may prescribe Mounjaro for the approved diabetes indication while considering the person's heart failure. For someone without type 2 diabetes, using Mounjaro specifically for HFpEF would be off-label. In either case, the diagnosis on the prescription, product selected, dose, concurrent medicines, and follow-up plan are clinical decisions, not conclusions that can be copied from the trial design.

What to ask at a heart-failure visit

Questions that clarify whether the SUMMIT evidence is relevant include:

1. Is the diagnosis HFpEF, and what is the documented ejection fraction?
2. Does the person resemble the obesity-related population enrolled in SUMMIT?
3. Is tirzepatide being considered for an FDA-approved indication or specifically off-label for HFpEF?
4. Which symptoms or weight changes should trigger urgent assessment rather than a routine dose discussion?
5. Could gastrointestinal fluid loss, low blood pressure, kidney dysfunction, or another medicine alter the risk?
6. How will benefit be judged without treating a biomarker or scale reading as a stand-alone dosing command?

These questions preserve the useful clinical lesson from SUMMIT: treating obesity-related biology can improve outcomes in a defined HFpEF population. They also preserve the boundary the trial did not cross: it did not publish a universal Mounjaro heart-failure dosing protocol.